INTRODUCTION
According to the 2018 World Drug Report, an estimated 275 million people worldwide used drugs for nonmedical purposes at least once during 2016. More than 30 million people who use drugs suffer from drug use disorders, and approximately 10.6 million people inject drugs, with opioids causing the most harm and accounting for 76% of drug use-related deaths [1] . In 2017, the risk of acquiring HIV by people who inject drugs (PWID) was 22 times higher than for people who do not inject drugs [2] . Thus, it is estimated that as many as 1.3 million PWID globally are living with HIV [1] . Noninjecting drug use, particularly methamphetamine and cocaine, and alcohol use are also associated with increased risks of HV acquisition [3, On a regional level, countries of Eastern Europe and Central Asia are severely affected by substance use and its interrelation with HIV. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), unlike other regions in the world, countries of this region demonstrate neither reduction in HIV-related mortality nor in HIV incidence with a doubling in the annual number of new HIV infections noted in less than 20 years [15] . In addition, this region has one of the largest numbers of PWID, as well as the highest number of PWID who are living with HIV [1, 2] .
Central Asia includes five countries: Kazakhstan, the Kyrgyz Republic, Tajikistan, Turkmenistan and Uzbekistan with a total population of more than 60 million ethnically, culturally and religiously diverse people. The region is located on what has been called the 'Northern drug traffic route' and in this article, we primarily focus on three countries -Kazakhstan, the Kyrgyz Republic and Tajikistan. The most recent population size estimates show that there are 120 500 PWID in Kazakhstan (UNAIDS, 2016), 25 000 in the Kyrgyz Republic (UNAIDS, 2016) and 23 100 in Tajikistan (UNAIDS, 2015) . PWID and their sex partners remain the population most affected by HIV in the region. By the end of 2018, national HIV program data showed that approximately 40% of all PLHIV in Kazakhstan and the Kyrgyz Republic, and 30% in Tajikistan reported a history of injecting drug use in the past and/or were currently injecting drugs. Considering the potential underreporting of injection drug use because of stigmatization of this behavior, especially among women, the accurate proportion of HIV infections related to injection drug use might be even higher [16 & ].
Data from the last rounds of the national integrated bio-behavioral surveys (IBBS) show that HIV prevalence among PWID ranged from 0 to 25% across sentinel sites (geographical areas) in Kazakhstan (IBBS 2018), 9.5-24.0% across sites in the Kyrgyz Republic (IBBS 2016), and from 4 to 18.5% across sites in Tajikistan (IBBS 2018) . In addition, a large proportion of PWID also have hepatitis virus C (HCV) infection, with HCV antibody prevalence among PWID ranging from 36 to 99% across sentinel sites in Kazakhstan (IBBS, 2018) and 47-79% in the Kyrgyz Republic (IBBS, 2016). In Central Asia as in other parts of the world, PWID, especially those with an incarceration history, are at high risk of tuberculosis (TB) and TB-related mortality [17, 18] . Thus, for this region, the dual stigma of injection drug use and HIV as well as the high prevalence of comorbid conditions, such as hepatitis C virus (HCV) and tuberculosis, impacts the health and well being of this population [19] . 
CHALLENGES TO THE HIV CONTINUUM FOR PEOPLE WHO INJECT DRUGS

KEY POINTS
Sustainable HIV epidemic control among PWID will not be feasible without decriminalization of drug use and policy changes to enhance access to and uptake of health services by this population and reduce stigma and discrimination related to drug use.
Strong political will and sufficient national funding is crucially important to ensure access to and coverage of PWID with high-quality harm reduction interventions, such as needle and syringe programs, naloxone distribution programs, and opioid agonist therapy.
There is the urgent need for adoption of innovations and provision of a combination of evidence-based biomedical, behavioural, and structural interventions in a manner that is appropriate and sensitive to the needs of the PWID whether for prevention of HIV transmission or for management of HIV in the context of addiction. . PLHIV who had history of injection drug use released from prison were given a monthly injection of XR-NTX for 6 months, beginning with a week before their release. Participants on the XR-NTX arm of the study were more likely than the placebo group to improve viral suppression (30.3 vs. 18.5%); maintain viral suppression (30.3 vs. 27.3%), and less likely to lose viral suppression (7.6 vs. 33.3%) by 6 months. Findings from another study among 1613 PWID in Ukraine, a setting similar to Central Asia context in terms of HIV epidemic drivers and treatment coverage for opioid use disorders, showed that 28% of PWID were willing to initiate XR-NTX. Thus, XR-NTX offers an option for addiction treatment and ART adherence support especially for PWID who have shorter history of injection and who harbor negative attitudes regarding methadone maintenance therapy (MMT) [57 & ]. However, XR-NTX's high cost and lack of pharmacopeia registration makes it inaccessible in several countries in Central Asia.
INTERVENTIONS FOR PREVENTION OF HIV ACQUISITION
It is widely acknowledged that needle and syringe programs (NSPs) and OAT decrease HIV incidence among persons who inject opioids by reducing injecting drug use and sharing of injecting equipment [58] . Thus, the expansion of access to NSP and OAT is as critically important to prevention of HIV acquisition as it is for enhancing outcomes among PWID living with HIV.
In terms of interventions for primary prevention, the evidence of the efficacy of preexposure prophylaxis (PrEP) for prevention of HIV acquisition among individuals at substantial risk for HIV has generated interest in its potential value among PWID. The Bangkok PrEP Trial, conducted among ] showed that there was substantial interest in PrEP; however, both PWID and providers described several barriers to PrEP use, including fears that the high costs of PreP could reduce funding for harm reduction programs, such as NSP, and uncertainty about the effectiveness of PrEP among PWID. Further work is needed to explore the potential use of PrEP among PWID in Central Asia. Given the high proportion of HIV-positive PWID with unsuppressed virus and low rates of consistent condom use with regular partners, implementation of PrEP should also be explored among sex partners of PWID.
Lastly, combining use of index testing of injecting and sex partners of PWID with assays that identify recent HIV infection could be fruitful in identifying those at risk for HIV acquisition for prevention efforts while ensuring prompt initiation of HIV treatment for those found to be HIV positive to prevent further transmission of HIV [62] .
CONCLUSION
Control of the HIV epidemic among PWID will not be feasible without addressing fundamental factors that drive transmission of HIV and that impede engagement of HIV-positive PWID in effective care and treatment in the countries of Central Asia. Prevention of new HIV infections among PWID will require expanding access of PWID to key evidencebased primary prevention interventions, such as harm reduction programs, and OAT.
Efforts to ensure critical social enablers are essential to control of the HIV epidemic among PWID (Fig. 2 ). This will require prioritization of human rights over political agendas and over rigid moralistic attitudes. Decriminalization of drug use and other policy changes are needed including abandoning the existing requirement for mandatory collection of personal data as part of the registration of persons with substance use disorders, which may enhance access to and uptake of health services by this population and may facilitate reduction in stigma and discrimination related to drug use.
In addition, there is the urgent need for adoption of innovations, such as expansion of HIV testing at the community level, including self-testing options for PWID and their partners, as well as pursuit of PrEP as an additional HIV prevention intervention. Assessment of the feasibility and effectiveness of combinations of evidence-based biomedical, behavioral and structural interventions is needed. Such interventions need to be developed and implemented with active community engagement to inform their design and implementation and to take into account the needs of sub-populations of PWID, for example, substance-using youth and women. Ultimately, adoption of differentiated service delivery models is needed in order to tailor services to the needs of this population [63 & ]. With the decrease in external HIV funding for Central Asian countries, it becomes crucially important to garner strong political will and sufficient national funding are available to enable PWID to access the package of recommended interventions that have been shown to be effective in reducing HIV transmission among this population [64]: OAT must be acknowledged as a fundamental component of the management of opioid dependence and must be integrated with other relevant health services, such as HIV services and/or primary healthcare services.
In summary, successful control of the global HIV epidemic requires attention to addressing the contribution of substance use to continued transmission of HIV. It will also require overcoming deep societal prejudices regarding substance users and concerted efforts to shape the HIV response to their unique needs. Findings from this study suggest the need for interventions at individual and/or couple level, healthcare provider, healthcare system and at larger structural levels to address adherence barriers faced by PWID, which will eventually help increase viral suppression among this population, thus reducing or eliminating HIV transmission, and prevent the development of drug-resistant virus. In this study, patients retained (vs. not retained) in buprenorphine treatment were more likely to be referred for HCV specialty care, achieve an HCV-specific evaluation, be offered HCV treatment, and initiate HCV treatment. 54. This study described barriers to PrEP utilization. Individual-level barriers included low PrEP knowledge and limited HIV risk perception, concerns about PrEP side effects, and competing health priorities and needs because of drug use and dependence. Interpersonal-level barriers included negative experiences with healthcare providers and HIV-related stigma within social networks. Clinical barriers included poor infrastructure and capacity for PrEP delivery to PWID, and structural barriers related to homelessness, criminal justice system involvement, and lack of money or identification to get prescriptions. 
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